Why Viking Therapeutics Stock Bumped 3% Higher Today
A major C-suite change at a potential competitor was a key factor behind the rise of Viking Therapeutics (NASDAQ: VKTX) stock on Friday, which closed the trading session 3% higher. That figure was well higher than the 0.7% increase of the benchmark S&P 500 index.That rival is Novo Nordisk, which announced that its current CEO Lars Jørgensen is to vacate his position. Image source: Getty Images.Continue reading
A major C-suite change at a potential competitor was a key factor behind the rise of Viking Therapeutics (NASDAQ: VKTX) stock on Friday, which closed the trading session 3% higher. That figure was well higher than the 0.7% increase of the benchmark S&P 500 index.
That rival is Novo Nordisk, which announced that its current CEO Lars Jørgensen is to vacate his position.
Image source: Getty Images.
